Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Aptar Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Aptar Pharma Acquires Worldwide License for Orbital™ High Payload Dry Powder Inhaler
Details : Pharmaxis’ proprietary Orbital™ inhaler, a unique device designed to deliver high payload dry powder to the lungs.This unique platform was originally developed as a life cycle extending product for the Pharmaxis cystic fibrosis drug Bronchitol® (man...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 04, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Aptar Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : PXS-5505,Atezolizumab,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : University of Rochester
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer
Details : PXS‐5505 has progressed to a phase 2 clinical trial looking for evidence of disease modifying effects in the bone cancer myelofibrosis as a monotherapy so exploring its additional potential to address cancers where fibrosis is limiting the clinical ben...
Brand Name : PXS-5505
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 09, 2021
Lead Product(s) : PXS-5505,Atezolizumab,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : University of Rochester
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PXS-6302
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial
Details : The phase 1 trial of the drug known as PXS-6302 tested 4 different strengths formulated as an easy to apply cream in 4 subjects as a single dose, scaling to the highest dose applied daily for 7 days in a further 6 subjects.
Brand Name : PXS-6302
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 31, 2021
Lead Product(s) : PXS-6302
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mannitol API
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Aptar Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : As per agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device & further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to de...
Brand Name : Bronchitol
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 17, 2021
Lead Product(s) : Mannitol API
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Aptar Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : PXS-5505
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model
Details : PXS‐5505 is currently progressing well through a phase 1c/2 clinical trial looking for evidence of disease modifying effects in bone cancer myelofibrosis as a monotherapy.
Brand Name : PXS-5505
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 05, 2021
Lead Product(s) : PXS-5505
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PXS-5505
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Parexel Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial
Details : The phase 1c/2a trial MF‐101 aims to demonstrate that PXS‐5505 is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs.
Brand Name : PXS-5505
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 04, 2021
Lead Product(s) : PXS-5505
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Parexel Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PXS-6302
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pharmaxis Announces World First Clinical Trial of Treatment to Prevent Wound and Burns Scars
Details : Together Australian pharmaceutical and University of Western Australia will test Pharmaxis’s topical discovery, known as PXS-6302, which has shown promising pre-clinical results in restraining the enzymes that play a significant role in the development...
Brand Name : PXS-6302
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 31, 2021
Lead Product(s) : PXS-6302
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?